FDA probes deaths linked to Sarepta’s gene therapy for muscular dystrophy
THE U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients after receiving Sarepta Therapeutics’ gene therapy, Elevidys. In June, Sarepta reported a second death in a patient who had received its gene therapy, which raised concerns about… Continue reading FDA probes deaths linked to Sarepta’s gene therapy for muscular dystrophy